Bicycle Therapeutics, plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bicycle Therapeutics, plc
Early Data For Bicycle’s Nectin-4 Asset Shows Promising Duration In Urothelial Cancer
The UK-headquartered biotech’s peptide-toxin conjugate showed a prolonged duration of response in advanced urothelial cancer patients in an early-stage trial compared with current standard of care, raising hopes for a differentiated profile.
Deal Watch: Sanofi Offloads Established Products, Lilly Testing 3D-Printed Drugs
Specialty pharma Neuraxpharm is taking on 38 mature brands from Sanofi, in CNS, pain and vascular diseases. Lilly is working with Triastek on 3D printing technology for targeted release of drugs in specific regions of the gastrointestinal tract.
OMass Therapeutics: The 21st Century Vertex?
Hot on the heels of an oversubscribed series B round, OMass CEO and Rising Leader Ros Deegan spoke with In Vivo about her move from pharma to biotech, mass spectrometry and big dreams for the firm.
UK's Cambridge Keen To Challenge US Counterpart With Biotech Start-Ups
Cambridge Innovation Capital partner Robert Tansley tells Scrip that the UK has "a really strong history of innovation in biological sciences and Cambridge has been at the forefront” but this has not equated to a substantial number of biotech companies “where we have lagged significantly behind the US."
- Other Names / Subsidiaries
- Bicycle Therapeutics Limited
- Bicycle Therapeutics Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.